John L. Lamattina - 05 Jun 2026 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Reporting relationship: Director
Issuer ticker: LGND
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2026, 19:41:02 UTC
Prior SEC filing: 31 Mar 2026
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: John L. LaMattina

Key filing fact

John L. Lamattina filed Form 4 for LIGAND PHARMACEUTICALS INC (LGND) on 09 Jun 2026.

Key facts

This page summarizes John L. Lamattina's Form 4 filing for LIGAND PHARMACEUTICALS INC (LGND).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2026, 19:41.

Change

Previous filing in this sequence was filed on 31 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001216074 Primary reporting owner

LAMATTINA JOHN L

Relationship: Director
Address: 555 HERITAGE DRIVE, SUITE 200, JUPITER
Signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: John L. LaMattina
Signature date: 09 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LGND transaction

Common Stock

Award

Transaction value
Shares: +836
Change %: +2.7%
Price: $0.000000^*
Shares after: 31,560
Date: 05 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LGND transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +2,938
Change %
Price: $0.000000^*
Shares after: 2,938
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,938
Exercise price: $237.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Footnote F2

Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.